Goldman Sachs’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Goldman Sachs’s Portfolio VTAE Stock Details VTAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-80,701	Closed	-$1.69M	–	7308
2016 Q3	$1.69M	Buy	80,701 +21,751	+37%	+$250K	﹤0.01%	3977
2016 Q2	$636K	Buy	58,950 +9,506	+19%	+$81.3K	﹤0.01%	4620
2016 Q1	$328K	Buy	+49,444	New	+$450K	﹤0.01%	5185
2015 Q4	–	Sell	-26,881	Closed	-$296K	–	7555
2015 Q3	$296K	Buy	+26,881	New	+$286K	﹤0.01%	5620
2015 Q2	–	Sell	-162,261	Closed	-$1.9M	–	7588
2015 Q1	$1.9M	Buy	162,261 +130,700	+414%	+$1.76M	﹤0.01%	3832
2014 Q4	$525K	Buy	+31,561	New	+$461K	﹤0.01%	5235

Goldman Sachs's VTAE Position: Q4 2016 in Review

Goldman Sachs sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 80,701 shares — an estimated $1.69M sold.

Goldman Sachs first reported a position in VTAE in Q4 2014 and held it in 6 quarters. The position peaked at $1.9M in Q1 2015. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

Goldman Sachs reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
Goldman Sachs sold 80,701 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $1.69M.
Goldman Sachs first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q4 2014 and held it in 6 quarters.
Goldman Sachs's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $1.9M in Q1 2015.
0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on Goldman Sachs's 13F filing for Q4 2016, filed 14 Feb 2017.